236 related articles for article (PubMed ID: 31509235)
21. Risk of Second Primary Malignancies in Patients With Follicular Lymphoma: A United States Population-based Study.
Giri S; Bhatt VR; Verma V; Pathak R; Bociek RG; Vose JM; Armitage JO
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):569-574. PubMed ID: 28709798
[TBL] [Abstract][Full Text] [Related]
22. Risk for malignancies of infectious etiology among adult survivors of specific non-Hodgkin lymphoma subtypes.
Herr MM; Schonfeld SJ; Dores GM; Engels EA; Tucker MA; Curtis RE; Morton LM
Blood Adv; 2019 Jul; 3(13):1961-1969. PubMed ID: 31262739
[TBL] [Abstract][Full Text] [Related]
23. Racial differences in three major NHL subtypes: descriptive epidemiology.
Li Y; Wang Y; Wang Z; Yi D; Ma S
Cancer Epidemiol; 2015 Feb; 39(1):8-13. PubMed ID: 25560974
[TBL] [Abstract][Full Text] [Related]
24. Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant Hodgkin lymphoma: a report of 21 cases from the Nebraska Lymphoma Study Group.
Huang JZ; Weisenburger DD; Vose JM; Greiner TC; Aoun P; Chan WC; Lynch JC; Bierman PJ; Armitage JO
Leuk Lymphoma; 2004 Aug; 45(8):1551-7. PubMed ID: 15370206
[TBL] [Abstract][Full Text] [Related]
25. Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant hodgkin lymphoma. A report of 21 cases from the Nebraska Lymphoma Study Group.
Huang JZ; Weisenburger DD; Vose JM; Greiner TC; Aoun P; Chan WC; Lynch JC; Bierman PJ; Armitage JO;
Leuk Lymphoma; 2003 Nov; 44(11):1903-10. PubMed ID: 14738141
[TBL] [Abstract][Full Text] [Related]
26. Rituximab is not associated with increased risk of second primary malignancies in Israeli patients with diffuse large B cell lymphoma treated with RCHOP regimen.
Neeman Y; Perry C; Silverman B; Waintraub N; Avivi I
Leuk Lymphoma; 2020 Nov; 61(11):2638-2644. PubMed ID: 32611210
[TBL] [Abstract][Full Text] [Related]
27. Influence factors of the survival in colorectal cancer patients with second primary malignancy after surgery: A SEER database analysis.
Liu L; Chen B
Medicine (Baltimore); 2023 Oct; 102(40):e35286. PubMed ID: 37800769
[TBL] [Abstract][Full Text] [Related]
28. Second Primary Malignancies in CTCL Patients from 1992 to 2011: A SEER-Based, Population-Based Study Evaluating Time from CTCL Diagnosis, Age, Sex, Stage, and CD30+ Subtype.
Amber KT; Bloom R; Nouri K
Am J Clin Dermatol; 2016 Feb; 17(1):71-7. PubMed ID: 26386881
[TBL] [Abstract][Full Text] [Related]
29. Malignancies diagnosed before and after anal squamous cell carcinomas: A SEER registry analysis.
Jani KS; Lu SE; Murphy JD; Romesser PB; Jethwa KR; Li D; Chundury A; Wu AJ; Hathout L; Hallemeier CL; Jabbour SK
Cancer Med; 2021 Jun; 10(11):3575-3583. PubMed ID: 33960690
[TBL] [Abstract][Full Text] [Related]
30. Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States.
Shenoy PJ; Malik N; Nooka A; Sinha R; Ward KC; Brawley OW; Lipscomb J; Flowers CR
Cancer; 2011 Jun; 117(11):2530-40. PubMed ID: 24048801
[TBL] [Abstract][Full Text] [Related]
31. Risks for noncutaneous second primary malignancy in cutaneous malignant melanoma survivors: an analysis of data from the Surveillance, Epidemiology, and End Results (SEER) program.
Vakharia PP; Kelm RC; Orrell KA; Patel KR; Singam V; Ali Y; Rastogi S; Yousif R; Rangel SM; West DP; Nardone B
Int J Dermatol; 2020 Apr; 59(4):463-468. PubMed ID: 31971260
[TBL] [Abstract][Full Text] [Related]
32. A reassessment of primary thyroid lymphoma: high-grade MALT-type lymphoma as a distinct subtype of diffuse large B-cell lymphoma.
Skacel M; Ross CW; Hsi ED
Histopathology; 2000 Jul; 37(1):10-8. PubMed ID: 10931213
[TBL] [Abstract][Full Text] [Related]
33. Characterizing Lymphoma Incidence and Disparities for a Cancer Center Catchment Region.
Ayers AA; Lyu L; Dance K; Ward KC; Flowers CR; Koff JL; McCullough LE
Clin Lymphoma Myeloma Leuk; 2019 Nov; 19(11):699-708.e5. PubMed ID: 31494062
[TBL] [Abstract][Full Text] [Related]
34. Risk of second primary malignancies in survivors of pancreatic neuroendocrine neoplasms from 2000 to 2018.
Yang Z; Liu L; Leng K; Shi G
J Gastroenterol Hepatol; 2023 Sep; 38(9):1474-1484. PubMed ID: 37114675
[TBL] [Abstract][Full Text] [Related]
35. Second nonbreast malignancies after conservative surgery and radiation therapy for early-stage breast cancer.
Galper S; Gelman R; Recht A; Silver B; Kohli A; Wong JS; Van Buren T; Baldini EH; Harris JR
Int J Radiat Oncol Biol Phys; 2002 Feb; 52(2):406-14. PubMed ID: 11872286
[TBL] [Abstract][Full Text] [Related]
36. Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma.
Myers RM; Hill BT; Shaw BE; Kim S; Millard HR; Battiwalla M; Majhail NS; Buchbinder D; Lazarus HM; Savani BN; Flowers MED; D'Souza A; Ehrhardt MJ; Langston A; Yared JA; Hayashi RJ; Daly A; Olsson RF; Inamoto Y; Malone AK; DeFilipp Z; Margossian SP; Warwick AB; Jaglowski S; Beitinjaneh A; Fung H; Kasow KA; Marks DI; Reynolds J; Stockerl-Goldstein K; Wirk B; Wood WA; Hamadani M; Satwani P
Cancer; 2018 Feb; 124(4):816-825. PubMed ID: 29125192
[TBL] [Abstract][Full Text] [Related]
37. Cardiovascular mortality among patients with non-Hodgkin lymphoma: Differences according to lymphoma subtype.
Abuamsha H; Kadri AN; Hernandez AV
Hematol Oncol; 2019 Aug; 37(3):261-269. PubMed ID: 30916804
[TBL] [Abstract][Full Text] [Related]
38. Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008.
Donin N; Filson C; Drakaki A; Tan HJ; Castillo A; Kwan L; Litwin M; Chamie K
Cancer; 2016 Oct; 122(19):3075-86. PubMed ID: 27377470
[TBL] [Abstract][Full Text] [Related]
39. The Incidence Characteristics of Second Primary Malignancy after Diagnosis of Primary Colon and Rectal Cancer: A Population Based Study.
Guan X; Jin Y; Chen Y; Jiang Z; Liu Z; Zhao Z; Yan P; Wang G; Wang X
PLoS One; 2015; 10(11):e0143067. PubMed ID: 26571301
[TBL] [Abstract][Full Text] [Related]
40. Risk Assessment of Secondary Primary Malignancies in Nasopharyngeal Carcinoma: A Big-Data Intelligence Platform-Based Analysis of 6,377 Long-term Survivors from an Endemic Area Treated with Intensity-Modulated Radiation Therapy during 2003-2013.
Zhang LL; Li GH; Li YY; Qi ZY; Lin AH; Sun Y
Cancer Res Treat; 2019 Jul; 51(3):982-991. PubMed ID: 30309219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
